Moderna's new Covid-19 vaccine analysis 'giving weight' to annual boosting interval, company says
Moderna’s Covid-19 vaccine study suggests a longer interval between boosters is more beneficial in the general adult population, supporting the FDA’s previous proposal for an annual boosting strategy.
Moderna analyzed the efficacy of a single booster of its original vaccine in around 17,000 participants enrolled in its Phase III COVE study from Sept. 2021 to May 2022, the company announced Wednesday at the IDWeek conference in Boston. The trial included participants who received a booster shot roughly 12 to 13 months after their primary series, as well as those who initially received a placebo before moving to the open-label phase and were boosted after roughly eight months, according to Fran Priddy, executive director of clinical development in Moderna’s Covid vaccines unit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.